超声造影与增强CT评价肝癌射频消融疗效的研究  

Study on Therapeutic Effect of Hepatic Carcinoma with Radiofrequency Ablation by Enhanced Ultrasonography and CT

作　　者：赵芳[1] 张钧[1] 祝英乔[1] 宋莉萍[1] 高秀娟[1] 

机构地区：[1]吉林省肿瘤医院电诊科,长春市130012

出　　处：《中国超声医学杂志》2006年第2期125-127,共3页Chinese Journal of Ultrasound in Medicine

摘　　要：目的比较动态灰阶超声造影和增强CT在评价肝癌射频消融(RFA)疗效中的作用。方法对54例病理证实的69个肝癌病灶进行RFA治疗,并与增强CT检查结果进行比较。结果如果以RFA治疗后消融灶各期均无增强为肿瘤完全灭活的依据,则超声造影和增强CT诊断肝癌灭活的敏感性分别为96.8%、96.7%、特异性为85.7%、83.3%、准确性为95.7%、95.5%;2种方法比较差异无显著性意义(χ2检验,P>0.05)。病灶最大直径测值超声造影与增强CT无差异。超声造影显示新病灶数增多。结论超声造影是评价RFA疗效的有效方法,具有与增强CT同样的敏感性。Objective To investigate the role of enhanced ultrasonography and enhanced CT in evaluating the therapeutic response of hepatic carcinoma with radiofrequency ablation （RFA） . Methods 54 patients with 69 liver occupying lesions of pathologically proved were treated by RFA. All patients were given injection of new contrast agent, SonoVue, 10 minutes and 1 month after RFA treatment to evaluate the therapeutic response with EUS and ECT. Results If the lesion without enhancement all the phases after RFA were regarded as complete necrosis, and lesions with local enhancement were diagnosed as tumor residual, the sensitivity in evaluating therapeutic effect of hepatic carcinomawith EUS and ECT were 96.8% （60/62）, 96.7% （58/60）; specificity 85.7% （6/7）, 83.3% （5/6）; accuracy 95.7% （66/69）, 95.5% （63/66）, respectively. There were no significant differences between EUS and ECT. （P〉0. 05） . The size of the lesions measured on EUS was similar to the value of ECT. The number of the new lesions were increased on EUS than ECT and US. Conclusions EUS is a useful methods to assess the therapeutic effect of RFA, which has showed the same sensitivity with ECT.

关 键 词：超声造影 肝肿瘤 消融疗效 

分 类 号：R735.7[医药卫生—肿瘤] R735.705[医药卫生—临床医学]